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Intention-to-treat analysis with treatment
discontinuation and missing data
in clinical trials
Roderick Little*† and Shan Kang
Motivated by a recent National Research Council study, we discuss three aspects of the analysis of clinical tri-
als when participants prematurely discontinue treatments. First, we distinguish treatment discontinuation from
missing outcome data. Data collection is often stopped after treatment discontinuation, but outcome data could be
recorded on individuals after they discontinue treatment, as the National Research Council study recommends.
Conversely, outcome data may be missing for individuals who do not discontinue treatment, as when there is loss
to follow up or missed clinic visits. Missing outcome data is a standard missing data problem, but treatment dis-
continuation is better viewed as a form of noncompliance and treated using ideas from the causal literature on
noncompliance. Second, the standard intention to treat estimand, the average effect of randomization to treat-
ment, is compared with three alternative estimands for the intention to treat population: the average effect when
individuals continue on the assigned treatment after discontinuation, the average effect when individuals take a
control treatment after treatment discontinuation, and a summarymeasure of the effect of treatment prior to dis-
continuation. We argue that the latter choice of estimand has advantages and should receive more consideration.
Third, we consider when follow-up measures after discontinuation are needed for valid measures of treatment
effects. The answer depends on the choice of primary estimand and the plausibility of assumptions needed to
address the missing data. Ideas are motivated and illustrated by a reanalysis of a past study of inhaled insulin
treatments for diabetes, sponsored by Eli Lilly. Copyright © 2014 John Wiley & Sons, Ltd.
Keywords: clinical trials; dropouts; incomplete data; intention-to-treat analysis; missing data; treatment discon-
tinuation
1. Introduction
The analysis of randomized clinical trials for comparing treatments is straightforward when all partici-
pants take their assigned treatments and have outcomes recorded. Summary measures such as means can
be compared to assess treatment effects, and the randomization protects the comparison from measured
and unmeasured confounders of treatment differences.
The analysis and interpretation is complicated when individuals discontinue their assigned treatments
prematurely, and/or outcome measures are not recorded. It is important to distinguish between these two
issues [1]. Treatment discontinuation leads to missing outcome data when a study chooses not to follow
up participants who discontinue treatment. However, outcome data can be recorded for individuals who
discontinue their assigned treatment, and participants who remain on their assigned treatment can have
missing outcomes, as when they miss clinic visits.
This article has three main objectives. The first is to conceptualize treatment discontinuation as a form
of noncompliance and apply ideas from the so-called Rubin model of causal inference [2,3]. Specifically,
observed compliance to a treatment is a post-treatment variable, so simply restricting comparisons of
treatments to those who comply, as in ‘per-protocol analysis’, is flawed because observed compliance is a
consequence of the treatment. Angrist, Imbens, and Rubin [4] defined strata based onwhether participants
would comply with each of the treatments being compared and then defined the ‘complier-average causal
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effect’ (CACE) to be the treatment effect within the stratum of individuals who would comply with all
the treatments under comparison. This is a valid causal effect, but estimating it involves a missing data
problem, in that compliance status is only known for the treatment actually assigned to a participant. In
a seminal paper [5], Frangakis and Rubin generalize these ideas to post-treatment variables other than
compliance, by defining ‘principal strata’ based on values of these post-treatment variables under all the
treatments being compared. Thus, for the particular case of compliance, ‘principal compliers’ are defined
as individuals who would comply for any of the compared treatments, if assigned to them. For other
discussions, see [6–8]
Analogously, in the setting of treatment discontinuation, we define ‘principle discontinuation strata’
based on whether individuals would discontinue under each of the treatments being compared. Because
we only get to observe discontinuation for the treatment actually assigned, this leads to a problem of
missing data in this covariate, as distinct from missing data in the outcome arising when outcomes are
not measured after discontinuation.
Our second goal concerns the following recommendation of a recent National Research Council report
on missing data in clinical trials [9], which emphasizes the central role of the choice of causal estimand
in clinical trial inference with treatment discontinuation or analysis dropouts:
“ The trial protocol should explicitly define (a) the objective(s) of the trial; (b) the associated primary outcome
or outcomes; (c) how, when, and on whom the outcome or outcomes will be measured; and (d) the measures
of intervention effects, that is, the causal estimands of primary interest. These measures should be meaningful
for all study participants, and estimable with minimal assumptions. Concerning the latter, the protocol should
address the potential impact and treatment of missing data.”
We agree with the implication of this recommendation that current approaches to handlingmissing data
in clinical trials often fail to define the causal estimand clearly. Protocols propose methods of intention to
treat (ITT) analysis or per-protocol analysis, together with weighting, imputation, or maximum likelihood
methods to handle missing data, but the underlying estimand is often not explicitly stated. Expanding on
this issue, we describe some possible estimands for the ITT population and suggest that the methods for
handling treatment discontinuation and analysis dropout depend crucially on the choice of estimand; a
method that is appropriate for one estimand is not necessarily appropriate for another.
Our third goal is to provide a nuanced discussion of whether follow-up measures should be attempted
for participants who discontinue treatment. The aforementioned National Research Council report [9]
recommends that
“Trial sponsors should continue to collect information on key outcomes on participants who discontinue their
protocol-specified intervention in the course of the study, except in those cases for which a compelling cost-
benefit analysis argues otherwise, and this information should be recorded and used in the analysis.”
While we generally concur with this recommendation, we suggest that the necessity to record outcomes
after treatment discontinuation is not universal but depends on the choice of primary causal estimand,
and the need and plausibility of assumptions about missing data required to estimate it. This reinforces
the need to define the causal estimand and associated methods of analysis carefully.
The following clinical trial, which had substantial missing data and a complex mix of missing-data
issues, serves to motivate and illustrate our ideas:
Example: a clinical trial of inhaled insulin treatments for diabetes.
Eli Lilly and Company conducted a study that assessed the efficacy and safety of an inhaled antihy-
perglycemic medication for patients with type 2 diabetes, compared with the standard therapies based
on injected insulin Glargine. This randomized, parallel-group study recruited individuals experiencing
lack of control of glucose levels, as measured by the HbA1c laboratory test. There were three treatment
arms: the inhaled insulin (Inhaled) arm (n = 222) replaced once-daily insulin Glargine with mealtime
inhaled insulin; the Insulin Glargine (IG) arm (n = 223), continued insulin Glargine on an intensified
regimen; and a Combined arm (n = 115), which combined oncedaily insulin Glargine with mealtime
inhaled insulin. Major objectives were the following:
(a) To test for noninferiority of Inhaled compared with IG;
(b) To test superiority of Combined compared with IG; and
(c) To test superiority of Inhaled compared with IG.
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Table I. Inhaled insulin study: discontinuation and missing data in study groups by reason.
Missing/discontinuation Inhaled no Inhaled
Type status and reason Combined IG no rescue IG rescue rescue rescue All
0 Completed 25 47 1 24 18 115
1 Subject decision 10 12 0 30 3 55
2 Physician decision 5 3 0 6 1 15
3 Protocol violation 1 4 0 3 0 8
4 Adverse event 2 0 0 4 0 6
5 Death 1 0 0 1 0 3
6 Sponsor decision to 68 137 9 94 25 333
Terminate trial
7 Lost to follow up 3 10 0 13 0 26
IG, Insulin Glargine.
The primary outcome was mean change in HbA1c from baseline to 24 weeks. We analyze here a sec-
ondary outcome, change from baseline to 52 weeks, to emphasize missing data issues. Superiority was
concluded if the upper limit of the 95% confidence interval for a specified treatment difference was less
than zero. Non-inferiority was concluded if this upper limit was less than 0.4%, but greater than or equal
to 0.0%.
Measures of HbA1c were obtained at baseline and after 4, 12, 24, 38, and 52 weeks. The pri-
mary statistical analysis specified in the protocol was by ITT, including all randomized patients with
a baseline and at least one follow-up measure after baseline. Adjustments for missing data were lim-
ited to last observation carried forward (LOCF) for missing endpoints when earlier observations on
treatment were available.
Rescue treatments were specified in the protocol for individuals whose diabetes was not well controlled
in the Inhaled and IG arms. In the IG group, the rescue therapy consisted of a pre-prandial dose of insulin.
In the Inhaled group, the rescue medication consisted of the addition of Glargine. No rescue therapy was
specified for individuals in the Combined group.
Only 115 of the 560 individuals in the study completed it, mainly because of a sponsor decision to
terminate the trial early. Table I shows the distribution of discontinuation types and missing data in the
three treatment groups, classified by reason. Of the 48 completers in the IG group, one received rescue
therapy, and of the 42 completers in the Inhaled group, 18 received rescue therapy. Follow-up measures
were attempted for individuals who took rescue treatments, but in other situations where individuals
completely stopped the study, no outcome measures were recorded after discontinuation.
Table I distinguishes five classes of individuals who discontinue treatment because of their outcomes
or side effects (Types 1–5), and two classes of missing data that are unrelated to an individual-level
decision to discontinue treatment (Types 6 and 7). The most prevalent form of missing data was the
sponsor decision to terminate the study (Type 6), which is considered missing data because it was a
global decision unrelated to treatment and outcomes of specific participants. This kind of missing data is
often called administrative censoring. The treatment discontinuation types 1–5 are likely to be related to
side effects or lack of efficacy in controlling HbA1c levels, and this distinction influences the treatment
of missing data, as discussed further in the succeeding text. Treatment discontinuation prior to week 52
also leads to missing data for the outcome change in HbA1c levels between week 52 and baseline. We
discuss in the succeeding text the chosen method of imputation, LOCF, and propose an alternative choice
of outcome measure that avoids the need to impute measures after discontinuation.
The remainder of the article is organized as follows. In the next section, we formalize the distinction
between treatment discontinuation andmissing outcome data, in a simple setting. In Section 3, we discuss
four alternative estimands for the ITT populationwhen there is treatment discontinuation, and in Section 4
apply some of these alternatives to the Insulin trial data. Section 5 presents conclusions and discussion.
2. Treatment discontinuation and missing outcomes: two distinct missing
data problems
For notational simplicity, we consider in this section the comparison of two treatments, T =1 = new, T =
0= control. Let Y represent an outcomemeasure, and let Y0 denote a baseline measure of Y and Z be other
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Figure 1. Missing outcomes and treatment discontinuation.
baseline covariates, both of which we assume to be observed for all participants. Let Y1 denote the trial
outcomemeasure, which could be the change in Y from the baseline value. (In the inhaled insulin example
there were also intermediate measures between baseline and end point.) We use a different notation
to distinguish treatment discontinuation and missing outcome data. Let Dt denote discontinuation for
treatment t, taking value 1 if an individual discontinues treatment t and 0 otherwise, and let M1 denote
the missing data indicator forY1 , with value 1 if Y1 is missing and 0 otherwise.
With missing outcome data but no treatment discontinuation, the data are depicted in Figure 1A. Well-
studied ideas ofmissing data in longitudinal studies apply, as discussed in chapters 4 and 5 of [9] or [10]. A
key assumption of many methods is missing at random (MAR) [10,11], which in our setting, corresponds
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Table II. Classifications by treatment and principal compliance: (A) population propor-
tions; (B) population mean outcomes; (C) observed means, with discontinuers followed; (D)
observed means, with discontinuers not followed.
Treatment discontinuation principal stratum
D1 =0 D1 =1 D1 = 0 or 1
D0 =0 D0 =1 D0 =0 D0 =1 D0 =0 D0 =1 ALL
A. Population proportions
Assigned treatment T 1 𝛼1𝜋00 𝛼1𝜋01 𝛼1𝜋10 𝛼1𝜋11 𝛼1𝜋+0 𝛼1𝜋+1 𝛼1
0 𝛼0𝜋00 𝛼0𝜋01 𝛼0𝜋10 𝛼0𝜋11 𝛼0𝜋+0 𝛼0𝜋+1 𝛼0
ALL 𝜋00 𝜋01 𝜋10 𝜋11 𝜋+0 𝜋+1 1
B. Population means






















C. Observed means, discontinuers followed
Assigned treatment T 1 ȳ(0+)1 ȳ
(1+)
1 — — ȳ1
0 — — — — ȳ(+0)0 ȳ
(+1)
0 ȳ0
D. Observed means, discontinuers not followed
Assigned treatment T 1 ȳ(0+)1 — — — —
0 — — — — ȳ(+0)0 — —
that is, the distribution of Y1 given Z, Y0 and T is the same for participants with Y1 missing and partici-
pants with Y1 observed. Under this assumption, the predictive distribution of the missing values can be
estimated using the observed data, or weighted estimates can be developed [9]. If MAR is not plausible,
and there are no other covariates that characterize the difference between respondents and nonrespon-
dents, there is no information in the data to estimate differences in the distribution
[
Y1|Y0,T ,Z,M1 = 1
]
from the distribution [Y1|Y0,T ,Z,M1 = 0], and the National Research Council report generally advocates
a sensitivity analysis.
Our focus here is on treatment discontinuation. Following the principal stratification literature of non-
compliance [4, 5, 7, 8, 12, 13], we define principal discontinuation under treatment T = t, Dt, taking the
value 1 if an individual would discontinue if assigned treatment t, and 0 otherwise (t = 0 and 1). The
variable Dt is a principal stratifier, unaffected by the treatment actually assigned and is observed for the
treatment that is actually assigned, but is missing for the treatment that is not assigned. In this formulation,
treatment discontinuation leads to missing values in the covariate, principal discontinuation. The data are
illustrated graphically in Figure 1B, for situations where outcomes for discontinuers are recorded, and
Figure 1C, for situations where outcomes for discontinuers are not recorded. Technically, the mechanism
is MAR, because missingness depends only on the known covariate T . However, there are problems of
identification, because values of Dt are entirely missing for the treatment not assigned. Clearly, there are
also mixed situations not depicted in Figure 1, where outcomes are partly recorded and partly missing,
both for discontinuers and continuers.
Table II provides an alternative tabular depiction of the data and defines notation. The row classification
is the assigned treatment T , and the column classification is the four combinations of principal treatment
discontinuation for the two treatments. Table IIA defines the population proportions, and Table IIB defines
the population mean outcomes, in each of the cells. Table IIC indicates the observed sample means when
discontinuers are followed, and Table IID indicates the observed sample means when discontinuers are
not followed.
3. Alternative estimands for the intention-to-treat population
The International Conference on Harmonization E9 [14] defines ITT as follows:
“The principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of
the intention to treat a subject (i.e. the planned treatment regimen) rather than the actual treatment given. It has
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2015, 34 2381–2390
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the consequence that participants allocated to a treatment group should be followed up, assessed and analyzed
as members of that group irrespective of their compliance to the planned course of treatment.”
This definition has two aspects, (1) the population for which the inference is defined, and (2) the choice
of estimand measuring the treatment effect in that population. The ITT population is all randomized
participants, with individuals classified according to the treatment randomized as opposed to (say) the
treatment actually received [15]. Under a strict interpretation of the ICH definition, the ITT estimand is
a summary of the effect of randomization to treatment (ERT), such as the difference in means in the last
column of Table IIB:
𝛿ERT = 𝜇1 − 𝜇0, (3)
which averages over principal discontinuation strata, that is, ignores discontinuation status. Carpenter,
Roger, and Kenward [16] call the ERT the de facto estimand. When all discontinuers are followed up and
outcomes Y1 obtained, as in Table IIC, 𝛿ERT can be directly estimated by the sample means of Y1 in the
two treatment groups:
𝛿ERT = ȳ1 − ȳ0. (4)
On the other hand, when outcomes of discontinuers are not obtained, as in Table IID, 𝛿ERT is no longer
directly estimable and requires assumptions about the distributions of final outcomes of discontinuers in
the two treatment groups. Obviously, if the ERT is of primary interest, a direct estimate is only available
if outcomes are recorded for participants who discontinue treatment. This is a formal justification of
the previously-cited National Research Council recommendation [9] to seek to measure outcomes for
individuals who discontinue treatment. Indeed, if no discontinuers are followed up, the only empirical
information for imputation of outcomes of discontinuers lies in the outcomes of continuers, so strong and
perhaps dubious assumptions are required to estimate the ERT.
A key feature of ERT is that it incorporates the effects of any treatments the participants received
between discontinuation of their assigned treatment and the final measurement Y1. An advantage of this
feature is that it is arguably addressing a realistic scenario. The disadvantage is that the treatment effect
may include the effects of treatments other than the treatment under study, so the study is in effect assess-
ing a ‘treatment regimen’ that involves these other treatments. In many studies, the main interest is not a
treatment regimen but rather in the particular effects of the new treatment.
The ERT is not the only possible estimand that can be applied to the ITT population. Alternatives define
and estimate an ITT estimand for the counterfactual situation in which treatments other than the actual
treatment are given after discontinuation. Examples include the estimand if discontinuers had remained
on their assigned treatments [estimand under assigned treatment (EAT); this corresponds to what [16]
call the de jure estimand]; or the estimand if discontinuers had taken a control treatment (Estimand under
Control Treatment, ECT). This approach requires a method for imputing the outcomes of discontinuers
whether or not outcomes of discontinuers are recorded, since, at least for some, possibly unknown, set of
participants, the outcomes are counterfactual; on the other hand, observing the actual outcomes of discon-
tinuers may provide useful input into the imputation model. The utility of this approach ultimately rests
on the underlying scientific plausibility of the estimand and associated method for dealing with missing
data. For example, the EAT may not be a plausible estimand if individuals drop out of the treatment for
dose-related adverse events. In a study on treatments for Alzheimer disease, Little and Yau [17] estimate
the EAT and ECT as part of a sensitivity analysis.
Can the EAT and ECT be considered ITT estimands? They are defined for all participants according
to the group to which they are randomized, but they do not meet the aforementioned ITT principle in the
sense that not all participants are ‘followed up and assessed’. However, in practice, many clinical studies
fail to follow up and record outcomes for all participants and still claim to do an ITT analysis; so strict
application of the principle is often an unattainable ideal in practice. Semantics aside, in situations where
outcomes are (implicitly or explicitly) imputed for discontinuers, it seems important to be clear about
their assumed treatment post-discontinuation—the actual treatment received (as in ERT), the assigned
treatment (as in EAT), or some other treatment, such as the control treatment (as in ECT).
If data after discontinuation are missing, how plausible are alternative imputation methods for these
various estimands?We consider the situation depicted in Table II.Methods based on theMAR assumption
assume that
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[Y1|Y0,Z,T ,D1 = 1] = [Y1|Y0,Z,T ,D1 = 0],
which may be plausible if the target estimand is the EAT but seems unjustified if the target estimand is the
ERT or ECT, since imputing the outcomes of discontinuers based on continuers seems unjustified when
the nature of treatment after discontinuation has changed [17]. Both LOCF and BOCF impute Y1 = Y0
for discontinuers, which is only realistic if the average outcome for discontinuers to T = 1 does not
change between the baseline and final value. This seems a strong assumption that may be questionable
in many settings, and single imputation as in these methods has the potential to lead to underestimates of
uncertainty.
If the ITT estimand of interest is the ECT, it seems preferable to impute missing data in the treatment
group using the conditional distribution of Y1 given Y0 for individuals in the control group [17, 18].
Note that this sample includes both principal continuers and discontinuers to T = 1, who cannot be
distinguished in the control group, so this involves the assumption that
[Y1|Y0,Z,T = 1,D1 = 1] = [Y1|Y0,Z,T = 0], (5)
This assumption may be weakened by including and conditioning on covariates Z other than Y1. A similar
approach in the more general situation when there are intermediate measures is one of the options in the
sensitivity analysis in [17].
These imputation approaches all involve assumptions, which may be controversial. Our final measure
of treatment effect for the ITT population avoids the need to specify treatments and impute outcomes
after discontinuation. We define an ‘on-treatment summary’ (OTS) outcome based on measures recorded
prior to discontinuation. An example in a symptomatic trial is to obtain repeated outcome measures until
treatment discontinuation or the end of the study and measure the outcome as area under the curve of the
repeated measures until treatment discontinuation or the end of the study, with the baseline level set at
Y0. Another example is to define a composite binary success/failure measure, treating discontinuation as
a failure.
The advantage of an OTSmeasure is that it can be defined for all individuals in the group to which they
are randomized, yet it avoids assumptions required to impute measures after treatment discontinuation.
The disadvantage is that the outcome measure does not reflect any effects of treatment manifested after
discontinuation. For example, in studies of chronic disease treatments, survival time is often the primary
measure of interest, but time of death is not anOTSmeasure because it is not known for survivors censored
at the time of treatment discontinuation. To sum up, the utility of an OTS measure rests on its scientific
value for assessing the treatments.
4. Case study: clinical trial of insulin treatments for diabetes
In the insulin study, rescue treatments (a preprandial dose of insulin in the IG group, or addition of
Glargine in the Inhaled group) were specified in the protocol for individuals discontinuing treatment
in these arms. When estimating the ERT, these rescue therapies become part of a ‘treatment regimen’.
Because a substantial proportion of completers in the Inhaled group took the rescue therapy (Table I), the
outcomes in this arm do not reflect the sole effect of the Inhaled treatment. A strength of this study is that
the nature of the treatment regimen is clarified by specifying allowable rescue treatment(s) in the study
protocol. However, a substantial proportion of individuals discontinued treatment despite the availability
of rescue therapies (Reasons 1–5 in Table I), and were not followed, leaving a sizeable missing data
problem for our secondary outcome.
The columns labelled A in Table III show the results from applying the analysis specified in the proto-
col, with outcome the change in HbA1c between baseline and week 52, with missing values imputed by
the LOCF method. An analysis of covariance (ANCOVA) model is used with two dummy variables for
treatment group. Insulin secretagogue strata, country, and HbA1c at baseline are covariates. There are
559 patients in ITT dataset, and 28 of them are not used because of missing data. The 95% confidence
interval of ‘Inhaled’-‘IG’ is (−0.380, 0.027) so noninferiority of Inhaled is established, because the upper
limit is less than 0.4%, and superiority of Inhaled is not established because the interval includes zero.
The 95% confidence interval of ‘Inhaled+IG’-‘IG’ is (−0.626, −0.137), so superiority of the combined
treatment over IG is established.
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2015, 34 2381–2390
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Table III. Three ITT ANCOVA Analyses of Diabetes Data.
A. Outcome=Change B. Outcome=Transformed
from baseline Proportion of 52 weeks when on
to week 52 treatment and HbA1c ⩽ 7.5%
All types of missing B1. Admin censoring B2. Admin censoring
data treated by or loss to follow up or loss to follow up
LOCF imputation treated by MI treated by LOCF
Regressor Estimate p-value Estimate p-value Estimate p-value
(95% CI) (95% CI) (95% CI)
Intercept −0.50 0.003 0.48 <0.001 0.52 <0.001
(−0.83, −0.17) (0.38, 0.59) (0.41, 0.63)
‘Inhaled’-‘IG’ −0.18 0.090 0.08 0.068 0.09 0.067
(−0.38, 0.03) (−0.01, 0.17) (−0.01, 0.18)
‘Inhaled+IG’-‘IG’ −0.38 0.002 0.12 0.021 0.14 0.017
(−0.63, 0.14) (0.02, 0.23) (0.02, 0.25)
Taking insulin −0.08 0.847 −0.03 0.478 −0.05 0.333
secretagogue (−0.28, −0.13) (−0.12, 0.06) (−0.14, 0.05)
Baseline −0.47 <0.001 −0.24 <0.001 −0.26 <0.001
(centered to 0) (−0.57, −0.37) (−0.28, −0.20) (−0.30, −0.21)
Country (DF=10) — 0.585 0.158 0.009
MI, multiple imputation; LOCF, last observation carried forward.
For the chosen primary measure, change from baseline HbA1c, LOCF is effectively the same as mea-
suring the outcome as change from baseline to treatment discontinuation or censoring. For the case of
discontinuation, this means the length of time on drug is not part of the measure, which seems undesir-
able because this is an important aspect of the drug’s effectiveness. Another comment is that the protocol
(like many others) does not make clear the assumed nature of treatments after discontinuation. The LOCF
method effectively assumes no change in outcome after discontinuation, but under what treatment? If the
assumed measure is the average ERT, LOCF is clearly not realistic in the Inhaled (inhaled insulin) arm,
because a common reason for discontinuing treatment in the Inhaled arm was lack of control of diabetes,
and in reality, an alternative rescue treatment, specifically Glargine, would be applied in this group to
reduce HbA1c levels and bring the diabetes back into control. In summary, we feel that the choice of
estimand is unclear, and the plausibility of the LOCF imputation method is doubtful.
Turning to other ITT estimands, the EAT does not appear to be plausible for the Inhaled arm, because
individuals tended to discontinue treatment when the treatment failed to control the diabetes, and the
counterfactual of what would have happened if they stayed on this treatment is not realistic. The ECT,
where the control treatment is Glargine, seems close to ERT and more realistic, since Glargine was the
chosen rescue treatment for the Inhaled arm. However, this estimand is really assessing a combined
Inhaled + IG regimen, which may not be the primary interest for a trial assessing the effectiveness
of inhaled insulin alone. Also, the LOCF imputation method is overestimating the HbA1c levels for
discontinuers in the Inhaled arm, for the same reasons as stated previously for the ERT estimand.
Given the difficulties in the aforementioned approaches, we prefer an OTS measure to deal with treat-
ment discontinuation in this study. One such measure is the proportion of the 52 weeks from baseline
to endpoint for which the individual was on treatment and had HbA1c levels that are low enough for
the diabetes to be considered ‘under control’, namely below 7.5%. Time post discontinuation is included
in the denominator but not the numerator, so there is an implicit penalty for discontinuing treatment, as
seems appropriate. This measure could be defined for the individual treatments, if time under control
while on rescue treatment was not included, or the treatment regimens, if time under control while on
rescue treatment was included.
This OTS approach addresses the issue of treatment discontinuation (Types 1–5 in Table I) but not the
issues of missing data because of loss to follow up or premature termination of the study (Types 6 and 7
in Table I). We need to impute the OTSmeasures for individuals with these missing data types. We do this
by a multiple imputation (MI) method, assumingMAR, that conditions on information prior to censoring
and allows for the possibility that individuals discontinue between the censoring time and 52 weeks.
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Because the pattern of missing data is monotone, the imputation is carried out sequentially from time
of termination of study (or loss to follow up) to 52 weeks, conditioning the imputations at each visit on
observed or imputed values from previous visits. For each missing visit, the algorithm is as follows:
Step 1: the missing HbA1c values are imputed as draws from their predictive distribution, based on
a model that includes treatment, previous recorded HbA1c values, whether rescue is initiated
prior to the missing value, and other covariates.
Step 2: Treatment discontinuation is imputed to have occurred at time t for subject i with probability
P(ti), where P(ti) is the prediction from a logistic regression model of discontinuation (yes,
no) on prior HbA1c values, whether rescue is initiated before, and other covariates.
Step 3: If treatment discontinuation is not imputed to happen at a visit, whether rescue therapy is
initiated at this visit is imputed based on a logistic regression of rescue (yes, no) on HbA1c
values for this visit and other covariates.
This algorithm is repeated to create 20 multiply imputed data sets, and MI combining rules used to
propagate imputation uncertainty (Rubin, 1987). The resulting data sets are analyzed by ANCOVA, with
an arcsine square root (sin−1
√
p) transformation of the proportions to stabilize the variance and reduce
skewness in the outcome distribution. The results are presented in the columns labeled B1 in Table III. The
results for the same analysis with LOCF imputation are included in the columns labeled B2 in Table III
for comparison.
The intercept is lower for MI (0.48) than for LOCF (0.52); hence under the MAR assumption for MI,
LOCF imputation results in an overstatement of the transformed proportion of the study period where
the diabetes is under control. Results comparing the treatment groups are similar for the two imputation
methods, with a marginally significant increase in transformed proportion for the Inhaled group over the
IG (p = 0.08. 95% CI = (−0.01, 0.16), and a statistically significant increase in transformed proportion
for the Combined group relative to the IG group (p = 0.022, 95% CI = (0.02, 0.23)). The statistical
significance of these results is comparable with those for the analysis specified in the protocol, in column
A of Table III; sizes of effects are not directly comparable because of the differences in outcomemeasures.
5. Conclusions
Our main points are as follows:
(a) Treatment discontinuation is distinguished as a different missing data problem from missing
outcome data, involving missing data in covariates defining principle discontinuation strata;
(b) Analyses of the ITT population based on estimands after treatment discontinuation need to be
clear about assumptions about the nature of treatments after discontinuation; in particular, the ERT
estimand includes any treatments administered after treatment discontinuation and the end of the
study, which may complicate the interpretation of treatment effects;
(c) Alternative estimands to ERT can be defined, such as EAT and ECT, that make counterfactual
assumptions about treatments after discontinuation. These need to be scientifically plausible, and
imputations after discontinuation need to be suitable for the assumed counterfactuals; and
(d) One way of avoiding these difficulties is to define an OTS measure of treatment effect based on
data prior to treatment discontinuation. This approach is illustrated using data from the inhaled
insulin study.
We have confined attention here to estimands for the ITT population. An issue not addressed is the
definition of treatment effects in subpopulations that are the target of per-protocol analysis. Based on prin-







which is analogous to the complier-average causal effect in the compliance literature [4]. The average
effects in the other principal discontinuation strata are also potentially of interest, but we suggest that the
CACE is usually the primary estimand of interest other than ITT. Estimation of this effect requires impu-
tation of the completer status for treatments other than the treatment actually received, which requires
additional assumptions, paralleling the situation with noncompliance; see, for example [7]. Application
of our framework to this type of estimand is a topic for future research.
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2015, 34 2381–2390
2389
R. LITTLE AND S. KANG
Acknowledgements
This research was supported as part of a Master Services Agreement 12-PAF01969 between the University of
Michigan and Eli Lilly, who kindly provided the data set. We greatly appreciate the assistance of Malgorzata Leyk
of Eli Lilly in helping us to understand the Insulin study data, and the referees and associate editor for constructive
comments.
References
1. Meinert CL. Toward more definitive clinical trials. Controlled Clinical Trials 1980; 1:249–261.
2. Rubin DB. Bayesian inference for causal effects: the role of randomization. The Annals of Statistics 1978; 6:34–58.
3. Holland PW. Statistics and causal inference. Journal of the American Statistical Association 1986; 81:945–970.
4. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables (with discussion and
rejoinder). Journal of the American Statistical Association 1996; 91:444–472.
5. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002; 58:21–29.
6. White IR. Uses and limitations of randomization-based efficacy estimators. Statistical Methods in Medical Research 2005;
14:327–347.
7. Little RJ, Long Q, Lin X. A comparison of methods for estimating the causal effect of a treatment in randomized clinical
trials subject to noncompliance. Biometrics 2009; 65(2):640–649.
8. Frangakis CE, Rubin DB. Addressing complications of intent-to-treat analysis in the combined presence of all-or-none
treatment-noncompliance and subsequent missing outcomes. Biometrika 1999; 86:365–379.
9. National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. The National Academies
Press: Washington, DC, 2010.
10. Little RJ, Rubin DB. Statistical Analysis with Missing Data, 2nd edition. Wiley: New York, 2002.
11. Rubin DB. Inference and missing data. Biometrika 1976; 63:581–592.
12. Little RJ, Yau L. Statistical techniques for analyzing data from prevention trials: treatment of no-shows using Rubin’s
causal model. Psychological Methods 1998; 3:147–159.
13. Peng Y, Little RJ, Raghunathan T. An extended general location model for causal inferences from data subject to non-
compliance and missing values. Biometrics 2004; 60:598–608.
14. Food and Drug Administration. Guidance for Industry, Vol. E9. Statistical Principles for Clinical Trials, 1998. http://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf.
15. White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for intention-to-treat analysis. Clinical
Trials 2012; 9:396–407.
16. Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol deviation: a framework for rele-
vant, accessible assumptions, and inference via multiple imputation. Journal of Biopharmaceutical Statistics 2013; 23(6):
1352–1371.
17. Little RJ, Yau L. Intent-to-treat analysis in longitudinal studies with drop-outs. Biometrics 1996; 52:1324–1333.
18. Ratitch B, O’Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using
pattern mixture models. Pharmaceutical Statistics 2013; 12(6):337–347.
2390
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2015, 34 2381–2390
